Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

101. Preparing HIV-infected children and adolescents for travel

, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr. 2008;49(3):272-5. 7. Crisinel PA, Posfay-Barbe KM, Aebi C, et al. Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. Clin Vaccine Immunol. 2012;19(11):1751-7. 8. Crane HM, Dhanireddy S, Kim HN, et al. Hepatitis A vaccination among human immuno- deficiency (...) . Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2000;30(1):218. 15. WHO. Vaccines and vaccination against yellow fever: WHO Position Paper. June 2013. http://www.who.int/wer/2013/wer8827.pdf?ua=1. 16. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48(5):659-66. 20 17. Staples JE, Bocchini JA, Jr., Rubin L

2018 The Children's HIV Association

102. Antiretroviral / HIV Drug Dosing for Paediatrics

Antiretroviral / HIV Drug Dosing for Paediatrics Antiretroviral / HIV Drug Dosing for Paediatrics 2018-19(v2) - Imperial College Healthcare NHS Trust (NOT for neonatal vertical transmission post exposure prophylaxis – see local / BHIVA guidelines) Agent Recommended dosage, class side effects and contraindications & warnings Formulation Comment Intake Advice Nucleoside Reverse Transcriptase Inhibitors (NRTI): lactic acidosis, steatosis, Lipoatrophy (effects of mitochondrial toxicity) Lamivudine (...) is intended to be used by practitioners experienced in paediatric HIV care. Please do not use this outside these recommendations. The table will be reviewed in June 2019 Tel: Family clinic: 020-3312-6349, Paed HIV Pharmacist: 020-3312-7617 Authors: Caroline Foster, Hermione Lyall, Gareth Tudor-Williams and Neil Tickner Please email feedback to: ntickner@nhs.net Version 4.1

2018 The Children's HIV Association

103. Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV

. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 Infection despite preexposure prophylaxis. New England Journal of Medicine. 2017;376(5):501–2. Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE [Electronic Resource]. 2016;11(6):e0157742. Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, et al. Acquisition of multidrug-resistant human immunodeficiency (...) drug-resistant mutations; the underlying cause for this infection remains unclear (15). Authors hypothesise infection with a “wild-type” HIV virus, and that frequent condomless anal sex, potential repeated exposure to HIV, repeated diagnosis of sexually transmitted infections, and the pharmacokinetics of TDF/FTC in rectal mucosa may have contributed to seroconversion (15). Practical considerations While daily oral TDF (with or without FTC) is protective against HIV infection, this is highly

2018 Ontario HIV Treatment Network

104. Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) ? Benefit assessment according to §35a Social Code Book (SGB) V

appropriate comparator therapy ARV antiretroviral EVG/COBI/FTC/TDF elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (fumarate) G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) HIV-1 human immunodeficiency virus type 1 IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) RCT randomized controlled trial SGB Sozialgesetzbuch (Social Code Book) Extract of dossier assessment A17-59 Version 1.0 EVG/COBI/FTC/TDF (HIV (...) was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as “the company”). The dossier was sent to IQWiG on 16 November 2017. Research question The aim of the present report was to assess the added benefit of EVG/COBI/FTC/TDF in comparison with the appropriate comparator therapy (ACT) in adolescents aged 12 to < 18 years with a body weight of = 35 kg who are infected with human immunodeficiency virus type 1 (HIV-1) without known mutations involving resistances against 1

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

105. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V

for Quality and Efficiency in Health Care (IQWiG) - vi - List of abbreviations Abbreviation Meaning ACT appropriate comparator therapy AE adverse event ATV/co cobicistat-boosted atazanavir ATV/r ritonavir-boosted atazanavir bPi boosted protease inhibitor DRV darunavir DRV/co cobicistat-boosted darunavir DRV/r ritonavir-boosted darunavir FTC emtricitabine G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) HIV-1 human immunodeficiency virus type 1 IQWiG Institut für Qualität und Wirtschaftlichkeit (...) to IQWiG on 27 September 2017. Research question The aim of this report was to assess the added benefit of DRV/COBI/FTC/TAF in comparison with the appropriate comparator therapy (ACT) in adults and adolescents (12 years of age and older and with a body weight of at least 40 kg) infected with human immunodeficiency virus type 1 (HIV-1). The G-BA's specification of the ACT resulted in 4 research questions, which are presented in the following Table 2. Table 2: Research questions of the benefit assessment

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

106. HIV, Sexually Transmitted Infection, and Substance Use Continuum of Care Interventions Among Criminal Justice-Involved Black Men Who Have Sex With Men: A Systematic Review Full Text available with Trip Pro

HIV, Sexually Transmitted Infection, and Substance Use Continuum of Care Interventions Among Criminal Justice-Involved Black Men Who Have Sex With Men: A Systematic Review Because Black men who have sex with men (BMSM) experience high rates of both HIV and incarceration relative to other groups, the various stages of criminal justice involvement may serve as important intervention points for addressing HIV and related conditions in this group. Although systematic reviews of HIV interventions (...) targeting MSM in general and BMSM in particular exist, no review has explored the range and impact of HIV, sexually transmitted infection (STI), and substance use prevention and care continuum interventions focused on criminal justice-involved (CJI) populations.To describe the range and impact of published HIV, STI, and related substance use interventions for US-based CJI populations and to understand their relevance for BMSM.We conducted systematic searches in the following databases: PubMed, MEDLINE

2018 EvidenceUpdates

107. Bictegravir, emtricitabine and tenofovir alafenamide (Biktarvy) - for the treatment of human immunodeficiency virus-1 (HIV-1)

Bictegravir, emtricitabine and tenofovir alafenamide (Biktarvy) - for the treatment of human immunodeficiency virus-1 (HIV-1) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located

2018 Health Canada - Drug and Health Product Register

108. Assessment of HIV-related mental status changes

Assessment of HIV-related mental status changes Assessment of HIV-related mental status changes - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of HIV-related mental status changes Last reviewed: February 2019 Last updated: October 2018 Summary Altered mental status and allied cognitive disorders have devastating consequences for HIV-infected individuals and their carers. Neuropsychological deficits also (...) have a negative impact on the quality of life. Pandya R, Krentz HB, Gill MJ, et al. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci. 2005 May;32(2):201-4. http://www.ncbi.nlm.nih.gov/pubmed/16018155?tool=bestpractice.com These may arise as a direct effect of HIV infection: for example, as part of a spectrum of HIV-associated neurocognitive disorders (HAND) or as a psychiatric comorbidity (e.g., depression or alcohol/substance abuse). While HIV-related

2018 BMJ Best Practice

109. ‘Why would you promote something that is less percent safer than a condom?’: Perspectives on partially effective HIV prevention technologies among key populations in South Africa Full Text available with Trip Pro

‘Why would you promote something that is less percent safer than a condom?’: Perspectives on partially effective HIV prevention technologies among key populations in South Africa New biomedical prevention technologies (NPTs) for HIV, including oral Pre-Exposure Prophylaxis, and vaginal and rectal microbicides and HIV vaccines in development, may contribute substantially to controlling the HIV epidemic. However, their effectiveness is contingent on product acceptability and adherence. We

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

110. ‘They care rudely!’: resourcing and relational health system factors that influence retention in care for people living with HIV in Zambia Full Text available with Trip Pro

‘They care rudely!’: resourcing and relational health system factors that influence retention in care for people living with HIV in Zambia Despite access to free antiretroviral therapy (ART), many HIV-positive Zambians disengage from HIV care. We sought to understand how Zambian health system 'hardware' (tangible components) and 'software' (work practices and behaviour) influenced decisions to disengage from care among 'lost-to-follow-up' patients traced by a larger study on their current (...) health status.We purposively selected 12 facilities, from 4 provinces. Indepth interviews were conducted with 69 patients across four categories: engaged in HIV care, disengaged from care, transferred to another facility and next of kin if deceased. We also conducted 24 focus group discussions with 158 lay and professional healthcare workers (HCWs). These data were triangulated against two consecutive days of observation conducted in each facility. We conducted iterative multilevel analysis using

2018 BMJ global health

111. An evaluation of the innovative potentials of a HIV pilot exploring medical pluralism in rural South Africa Full Text available with Trip Pro

An evaluation of the innovative potentials of a HIV pilot exploring medical pluralism in rural South Africa This article reflects on an internal evaluation undertaken to estimate the potentials of a community-university pilot project to be developed into a bonafide innovation that can be applied at scale. The focus of the community-university partnership has been to reduce the unintended consequences of medical pluralism on the HIV and AIDS epidemic in Waterberg district, Limpopo Province (...) , South Africa. Despite promising outputs from the partnership - including an increase in adherence to antiretroviral therapy and a reduction in stigma among traditionalists living with HIV - the partnership wished to establish whether further funding should be applied for to take the pilot from its current prototype status to a more established innovation. In order to evaluate the innovative potentials of the pilot, the opportunity vacuum model of innovation was adapted and applied. The findings

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

112. Determinants of disclosure and non-disclosure of HIV-positive status, by pregnant women in rural South Africa Full Text available with Trip Pro

Determinants of disclosure and non-disclosure of HIV-positive status, by pregnant women in rural South Africa Disclosure of HIV status remains one of the major challenges to the effectiveness of the prevention of mother to child transmission of HIV in rural areas in South Africa. This study aimed at assessing the determinants of HIV status disclosure among HIV infected pregnant women who have disclosed their HIV status to someone, as well as among those who have disclosed to their partners (...) . Cross-sectional data was collected from 673 HIV sero-positive pregnant women receiving antenatal care services at 12 Community Health Centers in Mpumalanga province. Results indicated that over two-thirds (72.1%) disclosed their status to someone, while just over half (58.4%) disclosed to their partners. Multivariate analysis showed that both disclosure of ones HIV status to someone and to their male partners was significantly associated with increase in antiretroviral therapy (ART) adherence

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

113. Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. Full Text available with Trip Pro

-HSCT.Nested case series within the IciStem observational cohort.Multicenter European study.6 HIV-infected, antiretroviral-treated participants who survived more than 2 years after allo-HSCT with CCR5 wild-type donor cells.HIV DNA analysis, HIV RNA analysis, and quantitative viral outgrowth assay were performed in blood, and HIV DNA was also measured in lymph nodes, ilea, bone marrow, and cerebrospinal fluid. A humanized mouse model was used for in vivo detection of the replication-competent blood cell (...) reservoir. HIV-specific antibodies were measured in plasma.Analysis of the viral reservoir showed that 5 of 6 participants had full donor chimera in T cells within the first year after transplant, undetectable proviral HIV DNA in blood and tissue, and undetectable replication-competent virus (<0.006 infectious unit per million cells). The only participant with detectable virus received cord blood stem cells with an antithymocyte globulin-containing conditioning regimen, did not develop graft-versus-host

2018 Annals of Internal Medicine

114. Effects of adolescent exposure to behaviour change interventions on their HIV risk reduction in Northern Malawi: a situation analysis Full Text available with Trip Pro

Effects of adolescent exposure to behaviour change interventions on their HIV risk reduction in Northern Malawi: a situation analysis Understanding adolescents' translation of HIV and AIDS-related behaviour change interventions (BCI) knowledge and skills into expected behavioural outcomes helps us appreciate behaviour change dynamics among young people and informs evidence-based programming. We explored the effects of adolescents' exposure to BCI on their HIV risk reduction in selected schools (...) model isolated sexual experience ([Beta = .727, p = .0001, p < .05]) as having the strongest correlation with the dependent variable - risk reduction. BCI exposure was stepwise excluded ([Beta = -.082, p = .053, p > .05]). There was therefore no evidence against the null hypothesis of no relationship between adolescent exposure to BCI and their HIV risk reduction. Overall there was limited BCI knowledge and skills translation to behavioural risk reduction. The study points to the need to evaluate

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

115. Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations

Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations - ACOG Menu ▼ Prenatal and Perinatal Human Immunodeficiency Virus Testing - Expanded Recommendations Page Navigation ▼ INTERIM UPDATE Number 752 (Replaces Committee Opinion No. 635, June 2015) Committee on Obstetric Practice HIV Expert Work Group This Committee Opinion was developed by the American College of Obstetricians (...) advances in the prevention of perinatal transmission of human immunodeficiency virus (HIV), it is clear that early identification and treatment of all pregnant women with HIV is the best way to prevent neonatal infection and also improve women’s health. Furthermore, new evidence suggests that early initiation of antiretroviral therapy in the course of infection is beneficial for individuals infected with HIV and reduces the rate of sexual transmission to partners who are not infected. Screening should

2018 American College of Obstetricians and Gynecologists

116. Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection

Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection - ACOG Menu ▼ Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection Page Navigation ▼ Number 751 (Replaces Committee Opinion No. 234, May 2000) Committee on Obstetric Practice HIV Expert Work Group The Society for Maternal–Fetal Medicine endorses this document. This Committee Opinion was developed (...) of pregnant women during pregnancy and delivery to prevent mother-to-child transmission of the human immunodeficiency virus (HIV). Prevention of transmission of HIV from the woman to her fetus or newborn is a major goal in the care of pregnant women infected with HIV. Continuing research into mother-to-child transmission of HIV has suggested that a substantial number of cases of perinatal HIV transmission occur as the result of fetal exposure to the virus during labor and delivery. The precise mechanisms

2018 American College of Obstetricians and Gynecologists

117. Doravirine (Pifeltro) - To treat HIV-1 infection in adult patients

Doravirine (Pifeltro) - To treat HIV-1 infection in adult patients Drug Approval Package: PIFELTRO (doravirine) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: PIFELTRO (doravirine) Company: Merck Sharp & Dohme Corp. Application Number: 210806 & 210807 Approval Date: 08/30/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2018 FDA - Drug Approval Package

118. Using strategic information for action: lessons from the HIV/AIDS response in Vietnam Full Text available with Trip Pro

Using strategic information for action: lessons from the HIV/AIDS response in Vietnam 30294455 2018 11 14 2059-7908 3 5 2018 BMJ global health BMJ Glob Health Using strategic information for action: lessons from the HIV/AIDS response in Vietnam. e000793 10.1136/bmjgh-2018-000793 Son Vo Hai VH Vietnam Administration on HIV/AIDS Control, Vietnam Ministry of Health, Hanoi, Vietnam. Abdul-Quader Abu A Center for Global Health, Centers for Disease Control and Prevention, Hanoi, Viet Nam. Suthar (...) Amitabh Bipin AB 0000-0001-9756-6593 Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. eng Journal Article 2018 09 26 England BMJ Glob Health 101685275 2059-7908 Hiv epidemiology geographic information systems health systems Competing interests: None declared. 2018 02 21 2018 05 07 2018 07 13 2018 10 9 6 0 2018 10 9 6 0 2018 10 9 6 1 epublish 30294455 10.1136/bmjgh-2018-000793 bmjgh-2018-000793 PMC6169661 Bull World Health Organ. 2010 Jan;88(1):58-65 20428354

2018 BMJ global health

119. Stick To It: pilot study results of an intervention using gamification to increase HIV screening among young men who have sex with men in California Full Text available with Trip Pro

Stick To It: pilot study results of an intervention using gamification to increase HIV screening among young men who have sex with men in California In the United States, young men who have sex with men (YMSM) experience a disproportionate burden of HIV and sexually transmitted infections (STIs). Mobile health (mHealth) interventions, including those that incorporate elements of games ("gamification"), have the potential to improve YMSM engagement in desirable sexual health services (...) and behaviors. Gamification leverages theory and tools from behavioral science to motivate people to engage in a behavior in a context of fun. The objective of the study was to determine whether an intervention using gamification is acceptable to YMSM in California and potentially increases repeat HIV screening.Eligible YMSM were: (I) 18-26 years, (II) born as and/or self-identified as male, (III) reported male sexual partners, and (IV) lived in a zip code adjacent to one of the two study clinics in Oakland

2018 mHealth

120. Exploring the acceptability of Option B plus among HIV-positive Nigerian women engaged and not engaged in the prevention of mother-to-child transmission of HIV cascade: a qualitative study Full Text available with Trip Pro

Exploring the acceptability of Option B plus among HIV-positive Nigerian women engaged and not engaged in the prevention of mother-to-child transmission of HIV cascade: a qualitative study The acceptability of lifelong antiretroviral therapy (ART) among HIV-positive women in high-burden Nigeria, is not well-known. We explored readiness of users and providers of prevention of mother-to-child transmission of HIV (PMTCT) services to accept lifelong ART -before Option B plus was implemented (...) in Nigeria. We conducted 142 key informant interviews among 100 PMTCT users (25 pregnant-newly-diagnosed, 26 pregnant-in-care, 28 lost-to-follow-up (LTFU) and 21 postpartum women living with HIV) and 42 PMTCT providers in rural North-Central Nigeria. Qualitative data were manually analyzed via Grounded Theory. PMTCT users had mixed views about lifelong ART, strongly influenced by motivation to prevent infant HIV and by presence or absence of maternal illness. Newly-diagnosed women were most enthusiastic

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance